|
Gene: TXNL4B |
Gene summary for TXNL4B |
Gene summary. |
Gene information | Species | Human | Gene symbol | TXNL4B | Gene ID | 54957 |
Gene name | thioredoxin like 4B | |
Gene Alias | DLP | |
Cytomap | 16q22.2 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9NX01 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54957 | TXNL4B | P74T-E | Human | Esophagus | ESCC | 5.94e-11 | 4.68e-01 | 0.1479 |
54957 | TXNL4B | P75T-E | Human | Esophagus | ESCC | 2.09e-16 | 2.48e-01 | 0.1125 |
54957 | TXNL4B | P76T-E | Human | Esophagus | ESCC | 6.85e-07 | 1.74e-01 | 0.1207 |
54957 | TXNL4B | P79T-E | Human | Esophagus | ESCC | 1.82e-20 | 2.67e-01 | 0.1154 |
54957 | TXNL4B | P80T-E | Human | Esophagus | ESCC | 1.53e-05 | 2.16e-01 | 0.155 |
54957 | TXNL4B | P82T-E | Human | Esophagus | ESCC | 6.50e-04 | 2.80e-01 | 0.1072 |
54957 | TXNL4B | P83T-E | Human | Esophagus | ESCC | 1.35e-14 | 4.27e-01 | 0.1738 |
54957 | TXNL4B | P89T-E | Human | Esophagus | ESCC | 6.10e-04 | 3.14e-01 | 0.1752 |
54957 | TXNL4B | P91T-E | Human | Esophagus | ESCC | 8.71e-05 | 5.30e-01 | 0.1828 |
54957 | TXNL4B | P107T-E | Human | Esophagus | ESCC | 6.01e-24 | 4.42e-01 | 0.171 |
54957 | TXNL4B | P127T-E | Human | Esophagus | ESCC | 2.45e-06 | 1.22e-01 | 0.0826 |
54957 | TXNL4B | P128T-E | Human | Esophagus | ESCC | 3.19e-14 | 3.27e-01 | 0.1241 |
54957 | TXNL4B | P130T-E | Human | Esophagus | ESCC | 2.41e-28 | 4.72e-01 | 0.1676 |
54957 | TXNL4B | HCC1_Meng | Human | Liver | HCC | 2.92e-11 | -1.35e-02 | 0.0246 |
54957 | TXNL4B | HCC2_Meng | Human | Liver | HCC | 7.73e-03 | -9.81e-03 | 0.0107 |
54957 | TXNL4B | HCC2 | Human | Liver | HCC | 3.66e-02 | 1.93e+00 | 0.5341 |
54957 | TXNL4B | S028 | Human | Liver | HCC | 2.59e-04 | 3.28e-01 | 0.2503 |
54957 | TXNL4B | S029 | Human | Liver | HCC | 5.02e-08 | 5.69e-01 | 0.2581 |
54957 | TXNL4B | C04 | Human | Oral cavity | OSCC | 9.00e-15 | 5.55e-01 | 0.2633 |
54957 | TXNL4B | C21 | Human | Oral cavity | OSCC | 4.02e-24 | 7.82e-01 | 0.2678 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TXNL4B | SNV | Missense_Mutation | c.200N>A | p.Ala67Glu | p.A67E | Q9NX01 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
TXNL4B | insertion | Nonsense_Mutation | novel | c.337_338insGATTTATTAGAAGGAGAGGGTAGGTGC | p.Ile113delinsArgPheIleArgArgArgGlyTerValLeu | p.I113delinsRFIRRRG*VL | Q9NX01 | protein_coding | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
TXNL4B | insertion | Nonsense_Mutation | novel | c.136_137insGGAGAGAGACCTAACCCAGAA | p.Ser46delinsTrpArgGluThrTerProArgThr | p.S46delinsWRET*PRT | Q9NX01 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
TXNL4B | insertion | Frame_Shift_Ins | novel | c.136_137insGTGGAGAGAGACCTAACCCAGAA | p.Ser46CysfsTer15 | p.S46Cfs*15 | Q9NX01 | protein_coding | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
TXNL4B | insertion | Nonsense_Mutation | novel | c.136_137insGGAGAGAGACCTAACCCAGAA | p.Ser46delinsTrpArgGluThrTerProArgThr | p.S46delinsWRET*PRT | Q9NX01 | protein_coding | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
TXNL4B | SNV | Missense_Mutation | c.202N>C | p.Val68Leu | p.V68L | Q9NX01 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TXNL4B | SNV | Missense_Mutation | c.200C>T | p.Ala67Val | p.A67V | Q9NX01 | protein_coding | deleterious(0.02) | benign(0.012) | TCGA-D5-5539-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fu | PD | |
TXNL4B | SNV | Missense_Mutation | c.252N>A | p.Phe84Leu | p.F84L | Q9NX01 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
TXNL4B | SNV | Missense_Mutation | c.263N>G | p.Gln88Arg | p.Q88R | Q9NX01 | protein_coding | tolerated(0.09) | benign(0.023) | TCGA-D1-A160-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TXNL4B | SNV | Missense_Mutation | novel | c.371T>C | p.Met124Thr | p.M124T | Q9NX01 | protein_coding | tolerated(0.13) | benign(0.18) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |